文献速递心力衰竭与心肌病

METTL3 是糖尿病心肌病运动获益的关键分子

METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.
PubMed 文献 · Circulation · 2025-05-13

该研究在糖尿病心肌病(DiaCM)小鼠模型和患者心肌组织中探讨 m6A 甲基转移酶 METTL3 的作用。结果显示,DiaCM 时心肌 METTL3 与 m6A 水平下调,运动可上调 METTL3;心肌细胞特异性 METTL3 敲除消除运动的心脏获益,而过表达 METTL3 或药物激活 METTL3 可改善 DiaCM 小鼠的心功能,其机制涉及 m6A 依赖的 YBX1 上调及 Nrf2 激活。

要点

  • DiaCM 患者和小鼠心肌 METTL3 与 m6A 水平下调,运动训练可上调 METTL3。
  • 心肌细胞 METTL3 敲除消除运动对 DiaCM 的心脏获益。
  • METTL3 通过 m6A-YBX1-Nrf2 轴减轻氧化应激并改善心功能。

核心结论

  • METTL3 在运动对糖尿病心肌病的心脏获益中起关键作用,METTL3 与 YBX1 是治疗 DiaCM 的潜在靶点。

研究设计与样本

  • 研究采用心肌细胞特异性 METTL3 敲除小鼠及其野生型同窝对照,分别给予普通饮食或高脂饮食联合链脲佐菌素注射诱导 DiaCM,随后进行 8 周运动训练并评估心功能。
  • 部分小鼠通过腺相关病毒载体在心肌细胞过表达 METTL3;另通过腺相关病毒载体过表达或敲低 YBX1 以检验其功能。
  • 研究还评估了非缺血性原发性扩张型心肌病患者(伴或不伴糖尿病)的心脏 METTL3 表达,并通过 RNA 测序鉴定下游效应分子 YBX1。

主要发现

  • 扩张型心肌病患者心脏 METTL3 蛋白表达和 m6A 水平下调,合并糖尿病者进一步下调;DiaCM 小鼠心脏 METTL3 和 m6A 亦下调,而运动可使其上调。
  • 心肌细胞特异性 METTL3 敲除消除了运动对 DiaCM 的心脏获益;反之,心肌细胞特异性 METTL3 过表达改善了 2 种 DiaCM 小鼠模型的收缩和舒张功能。
  • 运动通过信号转导与转录激活因子 3 增强 DiaCM 心脏 METTL3 表达;METTL3 通过 m6A 依赖的 YBX1 上调及随后 Nrf2 激活减轻 DiaCM。
  • 心肌细胞特异性 YBX1 过表达促进 Nrf2 激活并减轻氧化应激,改善 DiaCM 心功能;而 YBX1 基因敲低则消除 METTL3 对 DiaCM 小鼠心脏改善的作用。
  • 使用小分子药物激活 METTL3 可减轻 DiaCM 的心脏功能障碍。

临床怎么用

  • METTL3 及其下游 YBX1 可作为糖尿病心肌病的潜在治疗靶点,药物激活 METTL3 在动物模型中显示改善心功能的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism underlying cardiac benefits of exercise in DiaCM remains incompletely understood. N6-methyladenosine (m6A) is the most common form of messenger RNA modification in eukaryotes and has been implicated in cardiac development and disease. However, the role of m6A in DiaCM and in the mitigating effects of exercise on this disease are unclear. METHODS: Cardiomyocyte-specific N6-adenosine-methyltransferase-like 3 (METTL3, an m6A methyltransferase) knockout mice and their wild-type littermates were subjected to either chow diet or high-fat diet feeding and injection of streptozotocin to induce DiaCM, followed by an 8-week exercise training and assessment of cardiac function. Some of the mice were injected with adeno-associated viral vector encoding METTL3 to overexpress METTL3 in cardiomyocytes. Cardiac METTL3 expressions were assessed in patients with nonischemic primary dilated cardiomyopathies without or with diabetes. Potential METTL3 downstream effector YBX1 (Y-box binding protein 1) was identified through RNA sequencing. The functional role of YBX1 was examined through adeno-associated viral vector overexpression or knockdown in cardiomyocytes in DiaCM mice. RESULTS: We showed that cardiac METTL3 protein expression and m6A level were downregulated in patient with dilated cardiomyopathy and further downregulated in patients with dilated cardiomyopathy and diabetes. Consistently, cardiac METTL3 and m6A were downregulated in mouse with DiaCM, whereas they were upregulated by exercise. Cardiomyocyte-specific METTL3 knockout eliminated the cardiac benefits of exercise on DiaCM. Conversely, cardiomyocyte-specific METTL3 overexpression improved systolic and diastolic function in 2 DiaCM mouse models. We demonstrated that exercise enhanced cardiac METTL3 expression in DiaCM through signal transducer and activator of transcription 3. Moreover, METTL3 attenuated DiaCM through m6A-depdendent YBX1 upregulation and the subsequent activation of Nrf2. Cardiomyocyte-specific YBX1 overexpression promoted Nrf2 activation and attenuated oxidative stress, resulting in an improvement in cardiac function in DiaCM. In contrast, cardiomyocyte-specific YBX1 gene knockdown abolished the effect of METTL3 on cardiac improvement in mice with DiaCM. Further, pharmacological activation of METTL3 using a small molecule attenuated cardiac dysfunction in DiaCM. CONCLUSIONS: These studies reveal an essential role of METTL3 in the cardiac benefits of exercise and identify METTL3 and YBX1 as promising therapeutic targets for treating DiaCM.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wang C, Shen S, Kang J, et al. METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy. Circulation. 2025. PMID: 40357551. doi:10.1161/CIRCULATIONAHA.124.070279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。